Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Review

Anticoagulation management of post-cardiac surgery new-onset atrial fibrillation

Ghaith Alhatemi, MD, Mohamed Zghouzi, MD, Yasar Sattar, MD, Bachar Ahmad, BSc, Waqas Ullah, MD and M. Chadi Alraies, MD, MPH
Cleveland Clinic Journal of Medicine June 2022, 89 (6) 329-335; DOI: https://doi.org/10.3949/ccjm.89a.21003
Ghaith Alhatemi
Department of Internal Medicine, Saint Mary Mercy Hospital, Livonia, MI; Wayne State University/Detroit Medical Center, Detroit, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohamed Zghouzi
Department of Internal Medicine, Detroit Medical Center, Detroit, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasar Sattar
Department of Cardiology, West Virginia University, Morgantown, WV
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bachar Ahmad
Department of Internal Medicine, Detroit Medical Center, Detroit, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Waqas Ullah
Department of Cardiology, Thomas Jefferson University, Philadelphia, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Chadi Alraies
Director, Cardiac Catheterization Laboratory, Cardiac Rehabilitation and Interventional Cardiology Research, Department of Cardiovascular Medicine, Detroit Medical Center, Detroit, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

New-onset post-cardiac surgery atrial fibrillation (PCSAF) is a frequent complication with estimated incidence of 17% to 64%, depending on type of surgery. It is associated with higher mortality, morbidity, and predisposition to stroke and systemic embolism postoperatively. Standard care involves rate or rhythm control, in addition to antithrombotic therapy in those with history of stroke, transient ischemic attack, or high risk of systemic thromboembolism. However, risk of bleeding is not negligible, and treating physicians should weigh the risks and benefits before committing to postoperative anticoagulation therapy. More investigations are warranted to explore antithrombotic therapy benefit, particularly postoperative anticoagulation, considering the potentially self-limited nature of the arrhythmia and high risk of postoperative bleeding.

KEY POINTS
  • Anticoagulation should be weighed against potential risk of postoperative bleeding for patients with new-onset PCSAF as it is potentially transient and self-limited.

  • Avoid anticoagulation therapy for transient atrial fibrillation < 48 hours.

  • Anticoagulation is usually recommended for 4 to 6 weeks after atrial fibrillation conversion owing to enhanced risk of thrombosis resulting from persistent weak atrial contraction.

There is no exact consensus regarding the definition of new-onset post-cardiac surgery atrial fibrillation (PCSAF), and thus criteria for diagnosis are set by individual institutions. Our definition of new-onset atrial fibrillation is any duration detected on 12-lead electrocardiography or on a telemetry strip, developed in patients after cardiac surgery without previous diagnosis of atrial fibrillation, regardless of need for treatment. Cardiac surgery is defined as coronary artery bypass grafting (CABG), valve surgery, or a combination of both procedures. Studies have determined the postoperative timing of new-onset atrial fibrillation to range from the first 10 days postoperatively1 to the first 30 days after surgery,2 as well as during hospitalization only.3

The purpose of this review is to evaluate the studies, professional society recommendations, and expert thoughts on knowledge gaps relevant to anticoagulation therapy of new-onset PCSAF.

EPIDEMIOLOGY

With little change over the past 20 years, new-onset PCSAF is estimated to occur in the postoperative period in 17% to 40% after isolated CABG surgery,4–7 38% to 64% after heart valve surgery,3,4,7 and as high as 62% after combined procedures.1,3,4,6

New-onset PCSAF tends to develop within the first few days postoperatively,4,5 with the highest incidence seen on postoperative day 2, while most recurrence happens by postoperative day 3.5 Few patients develop new-onset atrial fibrillation in the very early postoperative period or 4 days or more after surgery.4

In patients who have no prior history of atrial fibrillation, new-onset PCSAF is usually transient in nature, as up to 80% revert to sinus rhythm within 24 hours,8 and the majority of patients (90%) are in sinus rhythm 6 to 8 weeks after discharge.4,9

THE IMPACT OF NEW-ONSET POST-CARDIAC SURGERY ATRIAL FIBRILLATION

Potential adverse events following new-onset PCSAF include thromboembolic complications, worsening of comorbid medical conditions, and increased mortality. Of interest, is the potentially increased rate of postoperative thromboembolic complications including stroke leading to the potential role of anticoagulation therapy in their prevention.10

Short-term complications

In multiple series, new-onset PCSAF had been associated with increased in-hospital postoperative stroke and increased mortality.3,6,11 These findings were similar in both on-pump (with cardiopulmonary bypass)3 and off-pump (without cardiopulmonary bypass) CABG surgery, and with and without valve surgery.11

On the other hand, other single-center studies failed to find an association between new-onset PCSAF and increased risk of in-hospital stroke.12,13 In one study, more than half of strokes occurred postoperatively rather than intraoperatively, and new-onset PCSAF was not associated with increased risk of stroke.13 However, older age and variables indicative of arteriosclerotic burden were risk factors for both intraoperative and postoperative stroke.13

Long-term complications

In most reports, new-onset PCSAF has been associated with worse long-term survival and increased thromboembolic complications.6,14–16 For instance, in the Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization trial of patients with left main coronary artery disease who underwent revascularization with either CABG or percutaneous coronary intervention, new-onset atrial fibrillation was an independent stroke predictor at three years in CABG patients.15

In another cohort study of patients who had undergone CABG surgery, risk of thromboembolism was lower in the PCSAF group than in the group with atrial fibrillation that was not valvular.14 Anticoagulation was associated with a lower risk of thromboembolic events in both groups, and thromboembolism was not significantly higher in patients with new-onset PCSAF compared with those who did not develop new-onset atrial fibrillation after surgery.

Risk of recurrence

There is considerable debate as to whether atrial fibrillation developing after cardiac surgery has a high risk of recurrence and thus whether extended anti-coagulation therapy to prevent thromboembolism can be beneficial. A recent meta-analysis analyzed 8 studies with a total of 1,157 participants monitored for new-onset PCSAF recurrence after discharge, all of whom were discharged in sinus rhythm and subsequently monitored by both noninvasive and invasive devices.17 Monitoring identified recurrence in 28.3 per 100 persons screened in the first 2 to 4 weeks after discharge using noninvasive techniques. Implanted devices identified recurrence in 61% to 100% of cases, suggesting that in-hospital PCSAF episodes are not transient. Most recurrences were asymptomatic and thus likely to be overlooked without the use of monitoring after hospital discharge.17

ANTICOAGULATION THERAPY FOR POST-CARDIAC SURGERY ATRIAL FIBRILLATION

Evidence behind anticoagulation and benefits

In medical patients with chronic or recurrent atrial fibrillation, the cause-and-effect relationship between atrial arrhythmias and thromboembolic events has been thoroughly examined18–21; however, this relationship has not been evaluated in the post-cardiac surgery setting. Current recommendations from the American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) 2014 and 2019 updated guidelines is to use warfarin (to target an international normalized ratio [INR] 2–3) and novel oral anticoagulants in patients with history of stroke, transient ischemic attack, or CHA2DS2-VASc score ≥ 2, defined as patients with congestive heart failure, hypertension, age ≥ 75, diabetes, stroke, vascular disease, age 65 to 74, and female.22,23

The question remains whether these guidelines are applicable to new-onset PCSAF in the postoperative period, taking into account the following facts:

  • Risk of bleeding may be significant in the postoperative period

  • CHA2DS2-VASc is a risk stratification tool that assesses annual stroke risk, however, has not been studied as an instrument for predicting postoperative stroke and embolic phenomena

  • In current literature, high-quality evidence of early postoperative antithrombotic therapy benefits in thromboembolic complications is lacking.

Kollar and colleagues24 described a retrospective study regarding benefits of anticoagulation in the postoperative period of 2,960 patients after CABG with 32 patients having had a postoperative stroke. The study was unique in that it examined the temporal relationship between postoperative atrial fibrillation and stroke. Seventeen of these patients continued to maintain sinus rhythm during their hospitalization. Of the remaining 15 patients, 9 had neurologic deficits before the first episode of atrial fibrillation. Of the 6 patients with atrial fibrillation preceding neurologic events, three strokes occurred within 1 week after spontaneous conversion to normal sinus rhythm. One patient with preoperative as well as intraoperative atrial fibrillation underwent emergency CABG surgery and woke up with a stroke. In the remaining two cases, the atrial fibrillation or atrial flutter episodes lasted less than 6 hours each before the onset of neurologic events. Authors concluded that aggressive anticoagulation as suggested in current guidelines could not have decreased the already low incidence of postoperative stroke.24 The study, however, was underpowered making it difficult to draw a conclusion that is generalizable to a large cohort. An adequately powered prospective registry evaluating the benefits of anticoagulation in the early postoperative period is warranted.

Risk of postoperative bleeding with anticoagulation

The questionable rationale of early anticoagulation in reducing postoperative stroke is impacted by the risk of associated bleeding in the postoperative period. For instance, there was a significant increase in large pericardial effusions and tamponade occurring one week or more after surgery in a study of patients treated with warfarin compared with the antiplatelet control group, especially when excessively anticoagulated (INR above therapeutic target).25

Bleeding other than at the surgical site might be relevant when determining use of anticoagulants, particularly with gastrointestinal hemorrhage. In a single-center, retrospective analysis of 9,017 patients undergoing cardiac surgery, the incidence of endoscopy-requiring gastrointestinal hemorrhage was 1.01%, and 30-day mortality was higher in patients who bled compared with patients who did not.26 The study was limited in that only bleeding events requiring intervention were included.

HAS-BLED is a risk score, defined as hypertension, abnormal renal or liver function, stroke, bleeding history or predisposition, labile INR, elderly (age > 65), and drugs or alcohol concomitantly, that is often used to determine use of anticoagulation therapy by evaluating risks and benefits in the general population with atrial fibrillation that is not valvular. However, validity in patients after surgery has not been evaluated.27 Thus, a high-quality risk stratification tool to identify bleeding in surgical patients would be of great clinical value.

Recommendations of professional societies

The AHA/ACC/HRS guidelines recommend considering using anticoagulation medication for patients who develop new-onset postoperative atrial fibrillation as administered for nonsurgical patients.22 The American College of Chest Physicians suggests weighing the AHA/ACC/HRS recommendations in the context of the usually transient and self-limited duration of new-onset PCSAF against the potential risk of bleeding and recommends starting anticoagulation therapy if atrial fibrillation persists 48 hours and beyond. They further state that therapy should be continued for 30 days after the return to normal sinus rhythm because of persistent atrial contraction impairment and possible enhanced risk of thrombosis following cardioversion to sinus rhythm.28 The Canadian Cardiovascular Society Atrial Fibrillation Guidelines recommend continuing anticoagulation for new-onset PCSAF for a minimum of 6 weeks,29 although the American College of Chest Physicians and AHA/ACC/HRS did not provide details regarding timing of initiation of antithrombotic therapy. A report from the European Association for Cardio-Thoracic Surgery does not recommend immediate full antithrombotic therapy when new-onset atrial fibrillation develops within 48 hours of cardiac surgery, due to increased risk of cardiac tamponade.30 Table 1 provides a summary of these recommendations,22,23,28–30 and Figure 1 shows our proposed algorithm for management of new-onset PCSAF.

View this table:
  • View inline
  • View popup
TABLE 1

Recommendations of professional societies

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Proposed algorithm for management of new-onset atrial fibrillation following cardiac surgery.

AF = atrial fibrillation; CHA2DS2-VASc = congestive heart failure, hypertension, age ≥ 75, diabetes, stroke, vascular disease, age 65 to 74, and female; PCSAF = post-cardiac surgery atrial fibrillation

Selection of drugs

The American College of Chest Physicians and AHA/ACC/HRS recommend anticoagulation therapy with warfarin, with or without heparin for atrial fibrillation.22,28 Novel oral anticoagulants have been included in the 2014 and 2019 updated AHA/ACC/HRS guidelines.22,23 More recently, the 2019 report added idarucizumab and andexanet alfa for the reversal of direct thrombin and activated factor Xa inhibitors, respectively.23

In one retrospective review, patients were administered anticoagulation with either warfarin or novel oral anticoagulants for new-onset PCSAF in the postoperative period; both drug classes were found to be safe and effective methods of anticoagulation with no significant difference between outcomes of strokes, postoperative hemorrhage, and hospital length of stay.31 The study was small and limited to the hospital postoperative period. Two other small pilot studies compared edoxaban32 and apixaban33 to warfarin for new-onset PCSAF and demonstrated safety and efficacy while suggesting larger scale clinical trials for further evaluation. A randomized clinical trial comparing rivaroxaban and warfarin for new-onset PCSAF is currently under way.34

Monitoring of therapy and discontinuation of anticoagulants

There is a lack of evidence regarding monitoring following discharge for new-onset PCSAF patients who revert to sinus rhythm before discharge. Consequently, some hospitals have developed institutional policies regarding follow up and monitoring of patients that relies on expert opinion. For instance, a feasibility cross-sectional study with a unique idea of self-monitoring assessed 42 patients who had undergone cardiac surgery (CABG, valve surgery, or combination) for new-onset PCSAF recurrence using smart phone handheld electrocardiogram devices.35 Study participants were instructed to record rhythm for 30 seconds, 4 times daily, for 4 weeks after discharge. Owing to the feasibility of the study, there was no control group, randomization, or blinding. Self-monitoring identified 24% with atrial fibrillation recurrence within 17 days of hospital discharge. Surprisingly, patients with atrial fibrillation recurrence were younger and had a lower CHA2DS2-VASc score than those without atrial fibrillation recurrence. Results should be interpreted with caution owing to the small sample size, infrequent self-monitoring, and study duration. Additional atrial fibrillation episodes may have been detected with a larger sample size and longer daily monitoring.

CONCLUSIONS

Adequately powered, large prospective studies are needed to investigate the relationship between transient atrial fibrillation and subsequent thromboembolic events in the postoperative period. Assessment of risk of hemorrhage in the immediate (first 48 hours) and later (≥ 48 hours to 7 days) postoperative period must be validated for cardiac surgery patients in large scale settings and may help to predict bleeding risk and allow for evaluation of postoperative anticoagulants. It is important to identify risk assessment models other than CHA2DS2-VASc score while considering operative technique to help identify patients at high risk in the setting of cardiac surgery. Finally, multicenter randomized trials investigating the benefits and risks of anticoagulation therapy indicated for transient atrial fibrillation early after cardiac surgery are warranted.

DISCLOSURES

The authors report no relevant financial relationships, which, in the context of their contributions, could be perceived as a potential conflict of interest.

  • Copyright © 2022 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Lee SH,
    2. Kang DR,
    3. Uhm JS, et al
    . New-onset atrial fibrillation predicts long-term newly developed atrial fibrillation after coronary artery bypass graft. Am Heart J 2014; 167(4):593–600.e1. doi:10.1016/j.ahj.2013.12.010
    OpenUrlCrossRefPubMed
  2. ↵
    1. Melduni RM,
    2. Schaff HV,
    3. Bailey KR, et al
    . Implications of new-onset atrial fibrillation after cardiac surgery on long-term prognosis: a community-based study. Am Heart J 2015; 170(4):659–668. doi:10.1016/j.ahj.2015.06.015
    OpenUrlCrossRefPubMed
  3. ↵
    1. Creswell LL,
    2. Schuessler RB,
    3. Rosenbloom M,
    4. Cox JL
    . Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 1993; 56(3):539–549. doi:10.1016/0003-4975(93)90894-n
    OpenUrlCrossRefPubMed
  4. ↵
    1. Maisel WH,
    2. Rawn JD,
    3. Stevenson WG
    . Atrial fibrillation after cardiac surgery. Ann Intern Med 2001; 135(12):1061–1073. doi:10.7326/0003-4819-135-12-200112180-00010
    OpenUrlCrossRefPubMed
  5. ↵
    1. Mathew JP,
    2. Fontes ML,
    3. Tudor IC, et al
    . A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004; 291(14):1720–1729. doi:10.1001/jama.291.14.1720
    OpenUrlCrossRefPubMed
  6. ↵
    1. Villareal RP,
    2. Hariharan R,
    3. Liu BC, et al
    . Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 2004; 43(5):742–748. doi:10.1016/j.jacc.2003.11.023
    OpenUrlFREE Full Text
  7. ↵
    1. Asher CR,
    2. Miller DP,
    3. Grimm RA,
    4. Cosgrove DM 3rd.,
    5. Chung MK
    . Analysis of risk factors for development of atrial fibrillation early after cardiac valvular surgery. Am J Cardiol 1998; 82(7):892–895. doi:10.1016/s0002-9149(98)00498-6
    OpenUrlCrossRefPubMed
  8. ↵
    1. Soucier RJ,
    2. Mirza S,
    3. Abordo MG, et al
    . Predictors of conversion of atrial fibrillation after cardiac operation in the absence of class I or III antiarrhythmic medications. Ann Thorac Surg 2001; 72(3): 694–698. doi:10.1016/s0003-4975(01)02817-x
    OpenUrlCrossRefPubMed
  9. ↵
    1. Lee JK,
    2. Klein GJ,
    3. Krahn AD, et al
    . Rate-control versus conversion strategy in postoperative atrial fibrillation: trial design and pilot study results. Card Electrophysiol Rev 2003; 7(2):178–184. doi:10.1023/a:1027428003609
    OpenUrlCrossRefPubMed
  10. ↵
    1. Shenasa M,
    2. Sanders P,
    3. Nattel S
    (eds). Risk Factors in Atrial Fibrillation: Appraisal of AF Risk Stratification, An Issue of Cardiac Electro-physiology Clinics, 1st ed. E-Book: Elsevier Health Sciences; March 2021.
  11. ↵
    1. Stamou SC,
    2. Dangas G,
    3. Hill PC, et al
    . Atrial fibrillation after beating heart surgery. Am J Cardiol 2000; 86(1):64–67. doi:10.1016/s0002-9149(00)00829-8
    OpenUrlCrossRefPubMed
  12. ↵
    1. Lotfi A,
    2. Wartak S,
    3. Sethi P,
    4. Garb J,
    5. Giugliano GR
    . Postoperative atrial fibrillation is not associated with an increase risk of stroke or the type and number of grafts: a single-center retrospective analysis. Clin Cardiol 2011; 34(12):787–790. doi:10.1002/clc.21001
    OpenUrlCrossRefPubMed
  13. ↵
    1. Tarakji KG,
    2. Sabik JF 3rd.,
    3. Bhudia SK,
    4. Batizy LH,
    5. Blackstone EH
    . Temporal onset, risk factors, and outcomes associated with stroke after coronary artery bypass grafting. JAMA 2011; 305(4):381–390. doi:10.1001/jama.2011.37
    OpenUrlCrossRefPubMed
  14. ↵
    1. Butt JH,
    2. Xian Y,
    3. Peterson ED, et al
    . Long-term thromboembolic risk in patients with postoperative atrial fibrillation after coronary artery bypass graft surgery and patients with nonvalvular atrial fibrillation. JAMA Cardiol 2018; 3(5):417–424. doi:10.1001/jamacardio.2018.0405
    OpenUrlCrossRef
  15. ↵
    1. Kosmidou I,
    2. Chen S,
    3. Kappetein AP, et al
    . New-onset atrial fibrillation after PCI or CABG for left main disease: the EXCEL Trial. J Am Coll Cardiol 2018; 71(7):739–748. doi:10.1016/j.jacc.2017.12.012.
    OpenUrlFREE Full Text
  16. ↵
    1. Saxena A,
    2. Dinh DT,
    3. Smith JA,
    4. Shardey GC,
    5. Reid CM,
    6. Newcomb AE
    . Usefulness of postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting (multicenter Australian study of 19,497 patients). Am J Cardiol 2012; 109(2):219–225. doi:10.1016/j.amjcard.2011.08.033
    OpenUrlCrossRefPubMed
  17. ↵
    1. Lowres N,
    2. Mulcahy G,
    3. Jin K,
    4. Gallagher R,
    5. Neubeck L,
    6. Freedman B
    . Incidence of postoperative atrial fibrillation recurrence in patients discharged in sinus rhythm after cardiac surgery: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg 2018; 26(3):504–511. doi:10.1093/icvts/ivx348
    OpenUrlCrossRef
  18. ↵
    1. Laupacis A,
    2. Boysen G,
    3. Connolly S, et al
    . Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154(13):1449–1457. pmid:8018000
    OpenUrlCrossRefPubMed
    1. Anderson DC,
    2. Halperin JL,
    3. Hart RG, et al; The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators
    . Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III study. JAMA 1998; 279(16):1273–1277. pmid:9565007
    OpenUrlCrossRefPubMed
    1. Hart RG,
    2. Halperin JL,
    3. Pearce LA, et al
    . Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med 2003; 138(10):831–838. doi:10.7326/0003-4819-138-10-200305200-00011
    OpenUrlCrossRefPubMed
  19. ↵
    1. Hart RG,
    2. Pearce LA,
    3. Aguilar MI
    . Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146(12):857–867. doi:10.7326/0003-4819-146-12-200706190-00007
    OpenUrlCrossRefPubMed
  20. ↵
    1. January CT,
    2. Wann LS,
    3. Alpert JS, et al
    . 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64(21):e1–e76. doi:10.1016/j.jacc.2014.03.022
    OpenUrlFREE Full Text
  21. ↵
    1. January CT,
    2. Wann LS,
    3. Calkins H, et al
    . 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74(1):104–132. doi:10.1016/j.jacc.2019.01.011
    OpenUrlFREE Full Text
  22. ↵
    1. Kollar A,
    2. Lick SD,
    3. Vasquez KN,
    4. Conti VR
    . Relationship of atrial fibrillation and stroke after coronary artery bypass graft surgery: when is anticoagulation indicated? Ann Thorac Surg 2006; 82(2):515–523. doi:10.1016/j.athoracsur.2006.03.037
    OpenUrlCrossRefPubMed
  23. ↵
    1. Malouf JF,
    2. Alam S,
    3. Gharzeddine W,
    4. Stefadouros MA
    . The role of anticoagulation in the development of pericardial effusion and late tamponade after cardiac surgery. Eur Heart J 1993; 14(11):1451–1457. doi:10.1093/eurheartj/14.11.1451
    OpenUrlCrossRefPubMed
  24. ↵
    1. Krawiec F,
    2. Maitland A,
    3. Duan Q,
    4. Faris P,
    5. Belletrutti PJ,
    6. Kent WDT
    . Duodenal ulcers are a major cause of gastrointestinal bleeding after cardiac surgery. J Thorac Cardiovasc Surg 2017; 154(1):181–188. doi:10.1016/j.jtcvs.2017.02.012
    OpenUrlCrossRef
  25. ↵
    1. Pisters R,
    2. Lane DA,
    3. Nieuwlaat R,
    4. de Vos CB,
    5. Crijns HJ,
    6. Lip GY
    . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5):1093–1100. doi:10.1378/chest.10-0134
    OpenUrlCrossRefPubMed
  26. ↵
    1. Epstein AE,
    2. Alexander JC,
    3. Gutterman DD,
    4. Maisel W,
    5. Wharton JM; American College of Chest Physicians
    . Anticoagulation: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 2005; 128(2 suppl):24S–27S. doi:10.1378/chest.128.2_suppl.24s
    OpenUrlCrossRefPubMed
  27. ↵
    1. Mitchell LB; CCS Atrial Fibrillation Guidelines Committee
    . Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention and treatment of atrial fibrillation following cardiac surgery. Can J Cardiol 2011; 27(1):91–97. doi:10.1016/j.cjca.2010.11.005
    OpenUrlCrossRefPubMed
  28. ↵
    1. Dunning J,
    2. Treasure T,
    3. Versteegh M,
    4. Nashef SA; EACTS Audit and Guidelines Committee
    . Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery. Eur J Cardiothorac Surg 2006; 30(6):852–872. doi:10.1016/j.ejcts.2006.09.003
    OpenUrlCrossRefPubMed
  29. ↵
    1. Anderson E,
    2. Johnke K,
    3. Leedahl D,
    4. Glogoza M,
    5. Newman R,
    6. Dyke C
    . Novel oral anticoagulants vs warfarin for the management of postoperative atrial fibrillation: clinical outcomes and cost analysis. Am J Surg 2015; 210(6):1095–1103. doi:10.1016/j.amjsurg.2015.07.005
    OpenUrlCrossRef
  30. ↵
    1. Sezai A,
    2. Osaka S,
    3. Yaoita H,
    4. Arimoto M,
    5. Hata H,
    6. Shiono M
    . Safety of the direct oral anticoagulant edoxaban for atrial fibrillation after cardiac surgery: pilot study. J Atr Fibrillation 2016; 9(3):1456. doi:10.4022/jafib.1456
    OpenUrlCrossRef
  31. ↵
    1. Chapin TW,
    2. Leedahl DD,
    3. Brown AB, et al
    . Comparison of anticoagulants for postoperative atrial fibrillation after coronary artery bypass grafting: a pilot study. J Cardiovasc Pharmacol Ther 2020; 25(6):523–530. doi:10.1177/1074248420929483
    OpenUrlCrossRef
  32. ↵
    1. ClinicalTrials.gov
    . Rivaroxaban vs warfarin for post-cardiac surgery atrial fibrillation (NEW-AF). https://clinicaltrials.gov/ct2/show/NCT03702582. Accessed May 18, 2022.
  33. ↵
    1. Lowres N,
    2. Mulcahy G,
    3. Gallagher R, et al
    . Self-monitoring for atrial fibrillation recurrence in the discharge period post-cardiac surgery using an iPhone electrocardiogram. Eur J Cardiothorac Surg 2016; 50(1):44–51. doi:10.1093/ejcts/ezv486
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 89 (6)
Cleveland Clinic Journal of Medicine
Vol. 89, Issue 6
1 Jun 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anticoagulation management of post-cardiac surgery new-onset atrial fibrillation
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Anticoagulation management of post-cardiac surgery new-onset atrial fibrillation
Ghaith Alhatemi, Mohamed Zghouzi, Yasar Sattar, Bachar Ahmad, Waqas Ullah, M. Chadi Alraies
Cleveland Clinic Journal of Medicine Jun 2022, 89 (6) 329-335; DOI: 10.3949/ccjm.89a.21003

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Anticoagulation management of post-cardiac surgery new-onset atrial fibrillation
Ghaith Alhatemi, Mohamed Zghouzi, Yasar Sattar, Bachar Ahmad, Waqas Ullah, M. Chadi Alraies
Cleveland Clinic Journal of Medicine Jun 2022, 89 (6) 329-335; DOI: 10.3949/ccjm.89a.21003
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • EPIDEMIOLOGY
    • THE IMPACT OF NEW-ONSET POST-CARDIAC SURGERY ATRIAL FIBRILLATION
    • ANTICOAGULATION THERAPY FOR POST-CARDIAC SURGERY ATRIAL FIBRILLATION
    • CONCLUSIONS
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Alpha-gal syndrome: Recognizing and managing a tick-bite–related meat allergy
  • Managing right ventricular failure in the setting of pulmonary embolism
  • Psychedelics, spirituality, and existential distress in patients at the end of life
Show more Review

Similar Articles

Subjects

  • Cardiology
  • Hospital Medicine

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire